Literature DB >> 12675506

Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Mansur E Shomali1, Laurence Katznelson.   

Abstract

Clinically nonfunctioning pituitary adenomas are one of the most common types of pituitary tumors. Unless they present with symptoms related to local mass effect, most tumors are detected incidentally when imaging studies are performed for other reasons. Although clinically nonfunctioning, most of these tumors have evidence, in vitro, of gonadotropin hormone or glycoprotein subunit production. The gonadotropins or their monomer submits rarely cause clinically identifiable effects. When these tumors present as macroadenomas, often with associated mass effect and hypopituitarism, primary therapy is neurosurgery. The role for medical therapy will be reviewed here.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12675506     DOI: 10.1023/a:1022312530900

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  98 in total

1.  Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors.

Authors:  A Klibanski; M A Shupnik; H A Bikkal; P M Black; B Kliman; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

2.  An immunohistochemical and ultrastructural study of a follicle-stimulating hormone-secreting gonadotroph adenoma occurring in a 10-year-old girl.

Authors:  H Tashiro; H Katabuchi; H Ohtake; A Yoshioka; S Matsumura; Y Suenaga; Y Nagamura; K Matsuura; H Okamura
Journal:  Med Electron Microsc       Date:  2000

3.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 4.  Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.

Authors:  I Shimon; T Rubinek; I Bar-Hava; D Nass; M Hadani; A Amsterdam; G Harel
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

5.  Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.

Authors:  A Klibanski; J L Jameson; B M Biller; W F Crowley; N T Zervas; J Rivier; W W Vale; H Bikkal
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

6.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

7.  In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).

Authors:  G Faglia; N Bazzoni; A Spada; M Arosio; B Ambrosi; F Spinelli; R Sara; C Bonino; F Lunghi
Journal:  J Clin Endocrinol Metab       Date:  1991-10       Impact factor: 5.958

8.  Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas.

Authors:  G Verde; G Oppizzi; P G Chiodini; D Dallabonzana; G Luccarelli; A Liuzzi
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

9.  Follicle-stimulating hormone-secreting pituitary tumor with concomitant elevation of serum alpha-subunit levels.

Authors:  J L Borges; E C Ridgway; K Kovacs; A D Rogol; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

10.  Glycoprotein hormone alpha-subunit secretion in prolactinomas and in non-functioning adenomas: relation with the tumour size.

Authors:  A Warnet; I Porsova-Dutoit; N Lahlou; D Seret-Begue; E Lajeunie; P Chanson; F Woimant; G Lot; P J Guillausseau; M Roger
Journal:  Clin Endocrinol (Oxf)       Date:  1994-08       Impact factor: 3.478

View more
  7 in total

1.  Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.

Authors:  George Vlotides; Emily Siegel; Ines Donangelo; Shiri Gutman; Song-Guang Ren; Shlomo Melmed
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 2.  Treatment of pituitary tumors: somatostatin.

Authors:  Maria A Tichomirowa; Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

3.  Isolation of tumour stem-like cells from benign tumours.

Authors:  Q Xu; X Yuan; P Tunici; G Liu; X Fan; M Xu; J Hu; J Y Hwang; D L Farkas; K L Black; J S Yu
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

4.  Pituitary incidentaloma: an endocrine society clinical practice guideline.

Authors:  Pamela U Freda; Albert M Beckers; Laurence Katznelson; Mark E Molitch; Victor M Montori; Kalmon D Post; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-04       Impact factor: 5.958

5.  A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma.

Authors:  Jing Guo; Zhuang Wang; Yazhou Miao; Yutao Shen; Mingxuan Li; Lei Gong; Hongyun Wang; Yue He; Hua Gao; Qian Liu; Chuzhong Li; Yazhuo Zhang
Journal:  Oncol Rep       Date:  2018-11-02       Impact factor: 3.906

Review 6.  Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal.

Authors:  Richard Santen; Farhad Hasan; Katie Thoren; Azeez Farooki
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

7.  Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.

Authors:  Jing Guo; Qiuyue Fang; Yulou Liu; Weiyan Xie; Yazhuo Zhang; Chuzhong Li
Journal:  Oncol Lett       Date:  2021-02-08       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.